Which ETFs hold CMPS? Compass Pathways PLC is held by 1 fund tracked by ETFpeek.

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 3 Aug 2026 | Kabir Nath CEO & Executive Director | SELL | Vested (RSU) | 5,962 | $67K | 0 |
| Date | Fund | Direction | Shares Changed | % Δ ETF | % Δ Position |
|---|---|---|---|---|---|
| 27 Jul 2026 | ARKG | BUYAdded | +107,130 | +0.03% | 2.34% |
| 24 Jul 2026 | ARKG | BUYAdded | +31,016 | -0.03% | 0.71% |
| 23 Jul 2026 | ARKG | BUYAdded | +42,088 | +0.06% | 0.96% |
| 21 Jul 2026 | ARKG | BUYAdded | +238,047 | +0.12% | 5.47% |
| 20 Jul 2026 | ARKG | BUYAdded | +101,793 | +0.07% | 2.47% |
| 17 Jul 2026 | ARKG | BUYAdded | +395,990 | +0.19% | 9.95% |
| 13 Jul 2026 | ARKG | BUYAdded | +37,822 | +0.13% | 1.08% |
| 10 Jul 2026 | ARKG | BUYAdded | +46,302 | -0.10% | 1.33% |
| 9 Jul 2026 | ARKG | BUYAdded | +28,447 | +0.26% | 0.83% |
| 8 Jul 2026 | ARKG | BUYAdded | +191,070 | +0.23% | 5.55% |
| No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal. | |||||